CR11636A - Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos - Google Patents

Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos

Info

Publication number
CR11636A
CR11636A CR11636A CR11636A CR11636A CR 11636 A CR11636 A CR 11636A CR 11636 A CR11636 A CR 11636A CR 11636 A CR11636 A CR 11636A CR 11636 A CR11636 A CR 11636A
Authority
CR
Costa Rica
Prior art keywords
pharmaceutical compositions
same
compositions containing
antagonist activity
release factor
Prior art date
Application number
CR11636A
Other languages
English (en)
Inventor
Kazuyoshi Aso
Katsumi Kobayashi
Takafumi Takai
Takuto Kojima
Kazuyuki Tokumaru
Michiyo Mochizuki
Yasutaka Hoashi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR11636A publication Critical patent/CR11636A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporciona un compuesto de la formula (I): en donde X es un nitrogeno o CRx, Rx es un hidrogeno, etc., R1 es un grupo de hidrocarburo opcianalmente substituido etc., R2 es un grupo de hidrocarburo opcionalmente substituido.
CR11636A 2008-01-22 2010-08-18 Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos CR11636A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US655408P 2008-01-22 2008-01-22

Publications (1)

Publication Number Publication Date
CR11636A true CR11636A (es) 2010-11-04

Family

ID=40637104

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11636A CR11636A (es) 2008-01-22 2010-08-18 Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos

Country Status (26)

Country Link
US (2) US8785460B2 (es)
EP (1) EP2240485B1 (es)
JP (1) JP5431341B2 (es)
KR (1) KR20100130596A (es)
CN (1) CN101981031A (es)
AR (1) AR070218A1 (es)
AU (1) AU2009206936A1 (es)
BR (1) BRPI0907230A2 (es)
CA (1) CA2712347A1 (es)
CL (1) CL2009000116A1 (es)
CO (1) CO6230982A2 (es)
CR (1) CR11636A (es)
DO (1) DOP2010000226A (es)
EA (1) EA201070876A1 (es)
EC (1) ECSP10010414A (es)
GE (1) GEP20125637B (es)
IL (1) IL207074A0 (es)
MA (1) MA32438B1 (es)
MX (1) MX2010008039A (es)
NZ (1) NZ587215A (es)
PE (1) PE20091439A1 (es)
SG (1) SG189803A1 (es)
TW (1) TW200936591A (es)
UY (1) UY31604A1 (es)
WO (1) WO2009093747A1 (es)
ZA (1) ZA201005340B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2010093425A1 (en) 2009-02-11 2010-08-19 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011031818A2 (en) * 2009-09-11 2011-03-17 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
MY166866A (en) 2011-08-18 2018-07-24 Nippon Shinyaku Co Ltd Heterocyclic derivative and pharmaceutical drug
EP2825541B1 (en) 2012-03-16 2016-06-22 Vitae Pharmaceuticals, Inc. Liver x receptor modulators
JP6114815B2 (ja) 2012-03-16 2017-04-12 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 肝臓xレセプターモジュレーター
WO2014165816A1 (en) 2013-04-05 2014-10-09 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
CN103435618B (zh) * 2013-08-22 2016-03-23 中国药科大学 一种合成稠杂环化合物的方法
KR20170005868A (ko) * 2014-05-23 2017-01-16 액티브 바이오테크 에이비 S100-저해제로서 유용한 새로운 화합물
CN105859630B (zh) * 2015-01-22 2019-01-18 北京大学 一种咪唑酮衍生物的合成方法及应用
EP3356369B1 (en) 2015-10-01 2022-05-04 Idemitsu Kosan Co., Ltd Benzimidazolo[1,2-a]benzimidazole carrying triazine groups for organic light emitting diodes
EP3150604B1 (en) 2015-10-01 2021-07-14 Idemitsu Kosan Co., Ltd. Benzimidazolo[1,2-a]benzimidazole carrying benzimidazolo[1,2-a]benzimidazolylyl groups, carbazolyl groups, benzofurane groups or benzothiophene groups for organic light emitting diodes
WO2018220513A1 (en) * 2017-05-31 2018-12-06 Alembic Pharmaceuticals Limited An improved process for preparation of obeticholic acid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS516993A (en) 1974-07-05 1976-01-20 Dainippon Pharmaceutical Co Adeninjudotaino seiho
HUP0303653A3 (en) 2000-12-28 2006-05-29 Ono Pharmaceutical Co Tricyclic and heterocyclic derivative and pharmaceutical compositions containing them as the active ingredient
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
EP1637521B1 (en) 2003-06-23 2013-06-19 Ono Pharmaceutical Co., Ltd. Novel tricyclic heterocycle compound
US7897607B2 (en) 2004-04-07 2011-03-01 Takeda Pharmaceutical Company Limited Cyclic compounds
TWI370820B (en) * 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2008051533A2 (en) 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds
EP2125753A1 (en) 2006-12-29 2009-12-02 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds having crf antagonistic activity
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
CL2009000119A1 (es) 2008-01-22 2010-03-05 Boehringer Ingelheim Int Compuestos derivados de amino-bencimidazoles sustituidos; composicion farmaceutica; y su uso en el tratamiento del alzheimer.

Also Published As

Publication number Publication date
MA32438B1 (fr) 2011-07-03
BRPI0907230A2 (pt) 2019-09-24
EP2240485A1 (en) 2010-10-20
PE20091439A1 (es) 2009-10-19
SG189803A1 (en) 2013-05-31
TW200936591A (en) 2009-09-01
KR20100130596A (ko) 2010-12-13
AR070218A1 (es) 2010-03-25
US20100298287A1 (en) 2010-11-25
WO2009093747A1 (en) 2009-07-30
US8785460B2 (en) 2014-07-22
UY31604A1 (es) 2009-08-31
US8901141B2 (en) 2014-12-02
JP2011509923A (ja) 2011-03-31
EA201070876A1 (ru) 2011-04-29
NZ587215A (en) 2012-08-31
CL2009000116A1 (es) 2010-08-27
DOP2010000226A (es) 2010-10-15
JP5431341B2 (ja) 2014-03-05
US20090186879A1 (en) 2009-07-23
AU2009206936A1 (en) 2009-07-30
GEP20125637B (en) 2012-09-10
IL207074A0 (en) 2010-12-30
MX2010008039A (es) 2010-08-10
ECSP10010414A (es) 2010-09-30
CN101981031A (zh) 2011-02-23
CA2712347A1 (en) 2009-07-30
EP2240485B1 (en) 2014-10-15
ZA201005340B (en) 2011-10-26
CO6230982A2 (es) 2010-12-20

Similar Documents

Publication Publication Date Title
CR11636A (es) Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
BRPI0922366B8 (pt) composto, composição farmacêutica e uso de um composto
EA200970156A1 (ru) Пиридизиноновые производные
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
EA201170772A1 (ru) Органические соединения
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
PH12018502513A1 (en) Sulfonamide compound or salt thereof
UY31712A1 (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmacéuticas que los contienen
MX2010008375A (es) Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
UY28745A1 (es) Nuevos compuestos
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
MY150062A (en) Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
NO20085317L (no) Imidazoazepinonforbindelser
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
DE602007005387D1 (de) Ptors
MX2009004007A (es) Nuevos derivados de indol, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)